Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBITDA Margin (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed EBITDA Margin for 14 consecutive years, with 530.34% as the latest value for Q1 2026.

  • For Q1 2026, EBITDA Margin rose 69163.0% year-over-year to 530.34%; the TTM value through Mar 2026 reached 719.97%, up 46889.0%, while the annual FY2025 figure was 873.87%, 29260.0% up from the prior year.
  • EBITDA Margin hit 530.34% in Q1 2026 for Agios Pharmaceuticals, up from 608.89% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 530.34% in Q1 2026 and bottomed at 12156.85% in Q1 2022.
  • Average EBITDA Margin over 5 years is 1977.81%, with a median of 1228.29% recorded in 2024.
  • Year-over-year, EBITDA Margin soared 1054136bps in 2023 and then plummeted -9763bps in 2025.
  • Agios Pharmaceuticals' EBITDA Margin stood at 2300.97% in 2022, then surged by 35bps to 1496.23% in 2023, then grew by 22bps to 1165.3% in 2024, then soared by 48bps to 608.89% in 2025, then increased by 13bps to 530.34% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 530.34%, 608.89%, and 907.37% for Q1 2026, Q4 2025, and Q3 2025 respectively.